Literature DB >> 15072757

Respiratory herpes simplex virus type 1 infection/colonisation in the critically ill: marker or mediator?

Jan-Willem van den Brink1, Alberdina M Simoons-Smit, Albertus Beishuizen, Armand R J Girbes, Rob J M Strack van Schijndel, A B Johan Groeneveld.   

Abstract

BACKGROUND: The clinical significance and pulmonary pathogenicity of herpes simplex virus type 1 (HSV-1) in mechanically ventilated, critically ill patients are unclear.
OBJECTIVE: To determine the clinical features and course of respiratory HSV-1 infections/colonisations in the critically ill, in order to evaluate the contribution to outcome.
DESIGN: A retrospective cohort study in the intensive care unit of an university hospital, involving 22 patients with a HSV-1 isolated from bronchoalveolar lavage (BAL) fluid, divided into survivors (n = 13) and non-survivors (n = 9). All patients except for one survivor had been intubated and were mechanically ventilated.
RESULTS: Non-survivors had acquired HSV-1 sooner on mechanical ventilation than survivors. Prior chronic heart disease was more prevalent in non-survivors than in survivors and, at the time of HSV-1 isolation, the mean creatinine level was higher (P < 0.05) in the former. Survivors had a somewhat greater fall in body temperature after a 10-day course of antiviral therapy than non-survivors, but the lung radiographic abnormalities prior to and after the course did not differ. There were no major differences in cardiorespiratory variables between outcome groups and causes of death and were judged not to relate, in general, to HSV-1.
CONCLUSIONS: Critically ill patients in whom HSV-1 from BAL is isolated, have about 40% chance of dying, mainly because of severe underlying disease and comorbidity, which may predispose to endogenous reactivation of the virus. There is no clinical evidence for direct cardiorespiratory pathogenicity and beneficial effects of antiviral therapy. HSV-1 isolated from lung secretions may thus be a marker rather than a mediator of severe illness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072757     DOI: 10.1016/j.jcv.2003.09.003

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  13 in total

Review 1.  Resistant pathogens, fungi, and viruses.

Authors:  Christopher A Guidry; Sara A Mansfield; Robert G Sawyer; Charles H Cook
Journal:  Surg Clin North Am       Date:  2014-10-03       Impact factor: 2.741

2.  The potential influence of common viral infections diagnosed during hospitalization among critically ill patients in the United States.

Authors:  Makesha Miggins; Anjum Hasan; Samuel Hohmann; Frederick Southwick; George Casella; Denise Schain; Huazhi Liu; Azra Bihorac; Lyle Moldawer; Philip Efron; Darwin Ang
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

3.  Herpes Simplex Pneumonia in an Immunocompetent Patient With Progression to Organizing Pneumonia.

Authors:  Brooke Mills; Atul Ratra; Amal El-Bakush; Shrinivas Kambali; Kenneth Nugent
Journal:  J Investig Med High Impact Case Rep       Date:  2014-04-09

4.  Herpes simplex type 1 pneumonitis and acute respiratory distress syndrome in a patient with chronic lymphatic leukemia: a case report.

Authors:  Miriam Luginbuehl; Alexander Imhof; Alexander Klarer
Journal:  J Med Case Rep       Date:  2017-11-23

5.  The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients.

Authors:  Daniel J Lachant; Daniel P Croft; Heather McGrane Minton; Dwight J Hardy; Paritosh Prasad; R Matthew Kottmann
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

6.  Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia.

Authors:  Atsuhito Ushiki; Yoshitaka Yamazaki; Mineyuki Hama; Masanori Yasuo; Masayuki Hanaoka; Keishi Kubo
Journal:  Respir Investig       Date:  2013-08-12

7.  Clinical course and spectrum of intensive care unit patients reactivating herpes simplex-1 virus: a retrospective analysis.

Authors:  Krishna M Sundar; Karl A Ludwig; William T Alward; Michael J Pearce; Clark T Bishop; Roy C Hammond; David R Hillyard; Steven W Freestone; Anne Ozment; Barbara C Cahill
Journal:  Indian J Crit Care Med       Date:  2008-10

8.  Herpes simplex virus type 1 and normal protein permeability in the lungs of critically ill patients: a case for low pathogenicity?

Authors:  Joanne Verheij; A B Johan Groeneveld; Albertus Beishuizen; Arthur van Lingen; Alberdina M Simoons-Smit; Rob J M Strack van Schijndel
Journal:  Crit Care       Date:  2004-03-31       Impact factor: 9.097

9.  Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation.

Authors:  Ilka Engelmann; Jens Gottlieb; Astrid Meier; Dorit Sohr; Arjang Ruhparwar; Cornelia Henke-Gendo; Petra Gastmeier; Tobias Welte; Thomas Friedrich Schulz; Frauke Mattner
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

10.  Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection.

Authors:  Christian Drosten; Michael Seilmaier; Victor M Corman; Wulf Hartmann; Gregor Scheible; Stefan Sack; Wolfgang Guggemos; Rene Kallies; Doreen Muth; Sandra Junglen; Marcel A Müller; Walter Haas; Hana Guberina; Tim Röhnisch; Monika Schmid-Wendtner; Souhaib Aldabbagh; Ulf Dittmer; Hermann Gold; Petra Graf; Frank Bonin; Andrew Rambaut; Clemens-Martin Wendtner
Journal:  Lancet Infect Dis       Date:  2013-06-17       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.